Daniel Ewing | July 22, 2020 11:21am
More »
Daniel Ewing | July 21, 2020 11:35am
More »
Daniel Ewing | July 20, 2020 4:28pm
More »
Recent Stock Announcements
Filter
Share Holder Notices
Annual Reports
Dividend Notices
Periodic Reports
Company Administration
Non-Procedural
Price Sensitive Only$ An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
Date
Heading
$ An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Time
Pages
File Size
«
‹
1
2
3
4
5
›
»
About Immuron Ltd (ASX: IMC)
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Share Price History
Data provided by Morningstar.
Date
Close
Change
% Change
Volume
Open
High
Low
16 Apr 2021
$0.19
$0.00
0.00%
174,771
$0.19
$0.19
$0.19
15 Apr 2021
$0.19
$0.00
0.00%
183,823
$0.19
$0.20
$0.19
14 Apr 2021
$0.19
$-0.01
-5.00%
221,692
$0.19
$0.20
$0.19
13 Apr 2021
$0.20
$0.00
0.00%
378,073
$0.19
$0.20
$0.19
12 Apr 2021
$0.20
$0.00
0.00%
230,597
$0.20
$0.20
$0.20
09 Apr 2021
$0.20
$0.01
5.13%
130,587
$0.20
$0.20
$0.20
08 Apr 2021
$0.20
$-0.01
-5.00%
98,813
$0.20
$0.20
$0.20
07 Apr 2021
$0.20
$0.00
0.00%
490,864
$0.21
$0.21
$0.20
06 Apr 2021
$0.21
$0.00
0.00%
139,323
$0.21
$0.21
$0.21
01 Apr 2021
$0.21
$0.00
0.00%
67,200
$0.20
$0.21
$0.20
31 Mar 2021
$0.20
$0.00
0.00%
37,339
$0.20
$0.21
$0.20
30 Mar 2021
$0.20
$0.00
0.00%
121,077
$0.20
$0.20
$0.20
29 Mar 2021
$0.20
$0.00
0.00%
174,488
$0.20
$0.21
$0.20
26 Mar 2021
$0.20
$0.00
0.00%
153,723
$0.20
$0.21
$0.20
25 Mar 2021
$0.20
$0.00
0.00%
419,796
$0.21
$0.21
$0.20
24 Mar 2021
$0.21
$0.00
0.00%
330,466
$0.21
$0.22
$0.21
23 Mar 2021
$0.21
$0.00
0.00%
17,317
$0.21
$0.21
$0.21
22 Mar 2021
$0.21
$0.00
0.00%
4,007
$0.21
$0.21
$0.21
19 Mar 2021
$0.21
$-0.01
-4.76%
214,780
$0.21
$0.21
$0.21
18 Mar 2021
$0.21
$-0.01
-4.65%
99,428
$0.21
$0.22
$0.21
17 Mar 2021
$0.22
$0.00
0.00%
595
$0.22
$0.22
$0.22
Show more
Director Transactions
Data provided by Morningstar.
Date
Director
Type
Amount
Value
Notes
09 Feb 2021
Ravi Savarirayan
Exercise
900
$207,000
09 Feb 2021
Ravi Savarirayan
Buy
409
$94,090
20 Nov 2020
Daniel Pollock
Sell
100
$26,000
13 Nov 2020
Peter Anastasiou
Issued
1
$459,000
13 Nov 2020
Stephen Anastasiou
Issued
468
$37,500
13 Nov 2020
Ravi Savarirayan
Issued
468
$37,500
13 Nov 2020
Peter Anastasiou
Issued
468
$37,500
13 Nov 2020
Ravi Savarirayan
Issued
1
$459,000
13 Nov 2020
Stephen Anastasiou
Issued
1
$459,000
13 Nov 2020
Roger Aston
Issued
1
$459,000
13 Nov 2020
Roger Aston
Issued
712
$57,000
13 Nov 2020
Daniel Pollock
Buy
29
$7,517
13 Nov 2020
Daniel Pollock
Issued
1
$459,000
13 Nov 2020
Daniel Pollock
Issued
618
$49,500
13 Nov 2020
Daniel Pollock
Sell
100
$27,000
13 Nov 2020
Daniel Pollock
Sell
29
$7,517
26 Jun 2020
Stephen Anastasiou
Sell
1
$150,674
26 Jun 2020
Peter Anastasiou
Sell
964
$79,104
23 Jun 2020
Roger Aston
Buy
56
$17,028
23 Jun 2020
Roger Aston
Exercise
144
$43,200
23 Jun 2020
Roger Aston
Expiry
3
$941,685
23 Jun 2020
Daniel Pollock
Buy
29
$8,844
23 Jun 2020
Daniel Pollock
Sell
100
$32,500
23 Jun 2020
Daniel Pollock
Exercise
74
$22,440
17 Jun 2020
Peter Anastasiou
Sell
4
$1,306,326
17 Jun 2020
Peter Anastasiou
Sell
1
$429,240
11 Jun 2020
Daniel Pollock
Sell
100
$40,480
Show more
Directors & Management
Data provided by Morningstar.
Name
Title
StartDate
Profile
Dr Roger Aston
Non-Executive Chairman,Non-Executive Director
May 2012
Mr Daniel Pollock
Non-Executive Director
Oct 2012
Mr Stephen Anastasiou
Non-Executive Director
May 2013
Mr Peter Anastasiou
Executive Director,Vice Chairman
May 2015
Mr Ravi Savarirayan
Non-Executive Director
Apr 2017
Mr Phillip Hains
Chief Financial Officer,Company Secretary
Apr 2013
Dr Jerry Kanellos
Chief Executive Officer
Mar 2020
Jerry Kanellos
Chief Executive Officer
Phillip Hains
Chief Financial Officer,Company Secretary
Show more
Top Share Holders
Data provided by Morningstar.
Name
Shares
Capital
HSBC Custody Nominees (Australia) Limited
104,631,009
46.57%
Grandlodge Pty Ltd And Its Related Holdings
11,778,269
5.26%
Authentics Australia Pty Ltd <Authentics Australia A/C>
7,500,000
3.35%
Dr Russell Kay Hancock
3,000,000
1.34%
Mr Stephen Anastasiou & Mrs Andria Anastasiou <Anastasiou Family S/F A/C>
2,494,746
1.11%
Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C>
2,000,000
0.89%
Citicorp Nominees Pty Limited
1,719,277
0.77%
Mr Anthony Frederick Wallace Hyett
1,350,000
0.60%
Anne Pattison Pty Ltd <Aep No 3 A/C>
1,345,000
0.60%
Mr William David Frank Bird
1,300,000
0.58%
Inverarey Pty Ltd <The Kilchurn A/C>
1,050,000
0.47%
Texas Woods Pty Ltd <The Plush Family A/C>
978,393
0.44%
Mr Nick Karopoulos
950,000
0.42%
Hadasit Medical Research Services & Development Ltd
887,462
0.40%
Peppertree Custodian Services Pty Ltd <Mulcahy Superannuation A/C>
860,634
0.38%
South Bay Nominees Pty Ltd <C & P Hong Family A/C>
850,000
0.38%
Mr David Anthony Plush & Mrs Ann Louise Plush <Plush Super Fund A/C>
834,075
0.37%
Mrs Rochelle Jane Pattison & Ms Katherine Margaret Forrest <Sylvan S/F A/C>
800,000
0.36%
Advance Publicity Pty Ltd <The Izmar Family A/C>
750,000
0.33%
Show more